ArticleData in brief2024
Bulk mRNA-sequencing data of the estrogen and androgen responses in the human prostate cancer cell line VCaP.
Article in Data in brief, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a hormone-dependent disease that relies on the androgen signaling, as well as on the estrogen signaling, for growth and survival. To identify the genes regulated by these sex-steroid hormones in the human prostate cancer cell line VCaP, these cells were treated for 24 h with either androgens and/or estrogens. Then, the RNA of each sample was purified for sequencing to generate bulk mRNA-seq data. After verifying raw quality, reads were pseudo-aligned on the human reference transcriptome (Gencode v27). Analysis was carried out on aligned and quantified data to determine the transcriptomic changes following each hormonal treatment. These data presented herein can be reanalyzed with specific fold-change thresholds for gene expression, or with different pair-wise combinations to compare the hormones' transcriptional impacts on VCaP cells and better understand prostate cancer cell biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.